**Integrating Viral and Nonviral Vectors for Cystic Fibrosis Gene Therapy in the Airways**

Ashley L Cooney, Paul B McCray, Jr and Patrick L. Sinn

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/60977

#### **Abstract**

[60] Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceed‐ ings of the National Academy of Sciences of the United States of America.

[61] Pedemonte N, Tomati V, Sondo E, Caci E, Millo E, Armirotti A, Damonte G, Zegarra-Moran O, Galietta LJ. Dual activity of aminoarylthiazoles on the trafficking and gat‐ ing defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. The Journal of Biological Chemistry.

[62] Knapp JM, Wood AB, Phuan PW, Lodewyk MW, Tantillo DJ, Verkman AS, Kurth MJ. Structure-activity relationships of cyanoquinolines with corrector-potentiator ac‐ tivity in ΔF508 cystic fibrosis transmembrane conductance regulator protein. Journal

[63] Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW. Progress in cystic fibrosis and the CF Therapeutics Development

of Medicinal Chemistry. 2012;55:1242-1251. DOI: 10.1021/jm201372q.

Network. Thorax. 2012;67:882-890. DOI: 10.1136/thoraxjnl-2012-202550.

2009;106:18825-18830. DOI: 10.1073/pnas.0904709106.

326 Cystic Fibrosis in the Light of New Research

2011;286:15215-15226. DOI: 10.1074/jbc.M110.184267.

An important goal for cystic fibrosis (CF) gene therapy is to achieve long-term functional correction. While many vector options have been evaluated, integrating vectors have the greatest potential to maintain stable expression over time without a requirement for repeated administration. In this chapter, we discuss the importance of correcting the appropriate cell types, options for integrating vectors, animal models for CF gene therapy, and clinically relevant endpoint measurements. Lentiviral vectors are a promising option for CF gene therapy, as they integrate into the host genome and persistently express a transgene of interest. Airway cell tropism can be conferred by pseudotyping. Nonviral vectors such as DNA transposons can also integrate into the genome. Recent advances in hybrid viral/transposon vector technology improve the ability to deliver transposons to the airways *in vivo*. Integrat‐ ing vector technology and new animal models have allowed considerable progress toward the goal of using gene therapy to correct life-long genetic diseases such as CF.

**Keywords:** lentivirus, transposons, animal models, progenitor cells, genotoxicity
